WASHINGTON — Eli Lilly and Co. said Wednesday its experimental Alzheimer's drug appeared to slow worsening of the mind-robbing disease in a large study.
In the 18-month trial, people in the early stages of Alzheimer's who received infusions of donanemab showed 35% less decline in thinking skills compared to those given a dummy drug, Lilly announced in a press release.
The drug is designed to target and clear away a sticky protein called beta-amyloid that builds up into brain-clogging plaques that are one hallmark of Alzheimer's.
A similar amyloid-targeting drug, Eisai and Biogen's Leqembi, recently hit the market with similar evidence that it could modestly slow Alzheimer's — and also some safety concerns, brain swelling or small brain bleeds.
Donanemab also comes with that risk. Lilly said in its study, the brain side effects caused the deaths of two participants and a third also died after a serious case.
The preliminary study results haven't been vetted by outside experts. Indianapolis-based Lilly plans to release more details at an international Alzheimer's meeting this summer and is seeking Food and Drug Administration approval of the drug.
2024-12-24 11:091915 view
2024-12-24 10:552116 view
2024-12-24 10:51328 view
2024-12-24 09:501122 view
2024-12-24 08:572524 view
2024-12-24 08:342682 view
ST. PETERSBURG, Fla. (AP) — A detailed assessment of the hurricane damage to Tropicana Field conclud
DENVER (AP) — Can former President Donald Trump run for his old job again after his role in the Jan.
WASHINGTON (AP) — The Supreme Court agreed on Friday to decide whether a Trump era-ban on bump stock